Landscapes / Companies

Celgene not checked

FollowEvery new trial, moved date and filing, and a Monday email
Furthest along
9 approved
3 in Phase 3
Next date
Elotuzumab, Phase 1/2 trial completes
Drugs
15
in active trials · 57 in all
Trials
22 active
170 since 2021

Drugs15

DrugHow it worksPartnerStageNext dateDetails
Monoclonal antibody
Bristol Myers Squibb
Approved 30 Nov 2026soonPhase 1/2 trial completes
Thalidomide analog
Approved 10 Jan 2027Phase 3 trial completes
Receptor molecules, native or modified
Approved 16 Jul 2027Phase 2 trial completes
—
Approved 16 Nov 2027Phase 3 trial completes
Nucleoside metabolic inhibitor
Approved 31 Jul 2028Phase 2/3 trial completes
Sphingosine 1-phosphate receptor modulator
Approved 29 Dec 2028Phase 4 trial completes
Isocitrate dehydrogenase 2 inhibitor
Approved —
Gene therapy substances
Approved —
Isocitrate dehydrogenase 1 inhibitor
Servier Bio-Innovation
Approved —
—
Phase 3 30 Nov 2026soonPhase 1/2 trial completes
—
Phase 3 7 Apr 2027Phase 1/2 trial completes
—
Phase 3 12 Sep 2027Phase 3 trial completes
—
Phase 2 26 May 2027Phase 2 trial completes
Gene therapy substances
Phase 2 26 Nov 2027Phase 1/2 trial completes
Monoclonal antibody
Phase 1 1 Aug 2028Phase 1 trial completes

About

No active trial
42 other drugs
SEC filings
None: it does not file with the US SEC
Sources
ClinicalTrials.gov updated 18 Nov 2026 Industry-sponsored drug trials since 2021

Follow Celgene

Following is part of Solo: you see every change to Celgene the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in